NCT07464028尚未招募2 期
Assessing Target Engagement for Terazosin in Parkinson's Disease (TZPD2)
Nandakumar Narayanan0 个研究点目标入组 120 人开始时间: 2026年7月1日最近更新:
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 120
- 主要终点
- ATP
研究概览
简要总结
This study investigates if Terazosin can improve metabolism in PD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 50 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Parkinson's disease
排除标准
- 未提供
研究组 & 干预措施
Active arm
Experimental
Terazosin 5 mg
干预措施: Terazosin 5 MG (Drug)
Placebo
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
ATP
时间窗: at 1.5 year
Changes in whole-blood ATP relative to baseline at 6 weeks and 1.5 years
次要结局
未报告次要终点
研究者
Nandakumar Narayanan
Professor
University of Iowa
相似试验
尚未招募
1 期
Terazosin And Metabolic Engagement in Parkinson's DiseaseParkinson's DiseaseNCT07288450Nandakumar Narayanan100
招募中
3 期
A clinical trial which runs in multiple countries and aims to evaluate the long-term safety and tolerability of the investigational product (TAVAPADON) for patients diagnosed with Parkinson's Disease.Parkinson's disease2024-512123-37-00Cerevel Therapeutics LLC487
招募中
不适用
Biological Determinants and Neural Compensation of Dysphagia in Parkinson's DiseaseNCT07299448Heinrich-Heine University, Duesseldorf100
招募中
不适用
A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in BelgiumParkinson's DiseaseNCT07382440AbbVie120
已完成
1 期
A Pilot Study of Terazosin for Parkinson's DiseaseParkinson DiseaseNCT03905811Jordan Schultz13